Price (delayed)
$2.06
Market cap
$100.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.86
Enterprise value
$120.21M
We are a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. Despite advances in treatment over the last
There are no recent dividends present for GUTS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.